Varicella Vaccine Immunity: Are We Measuring It Right?
"A closer look at the accuracy of current testing methods for varicella immunity and why re-evaluation may be needed for better protection."
For decades, the varicella vaccine has been a cornerstone of pediatric healthcare, significantly reducing the prevalence of chickenpox. The introduction of widespread vaccination programs has dramatically changed the landscape of this once common childhood ailment. With the success of these programs, there's an increasing need to accurately assess vaccine-induced immunity to ensure ongoing protection, especially as breakthrough infections still occur. This need has driven the development and use of various serological assays, each with its own strengths and limitations.
Among the array of available tests, the glycoprotein enzyme-linked immunosorbent assay (gpEIA) holds promise for its ability to detect and quantify antibodies against VZV. The VaccZyme™ VZV gpEIA kit, a commercially available assay, aims to standardize immunity measurements by using the WHO international standard as a calibrator. This article explores the effectiveness and reliability of the VaccZyme™ VZV gpEIA kit, comparing its results to the established fluorescent antibody to membrane antigen (FAMA) test, often considered the 'gold standard.'
We delve into a study conducted to evaluate the accuracy and reproducibility of the VaccZyme™ VZV gpEIA kit. This analysis seeks to determine whether current cutoff values—the thresholds used to define immunity—are appropriate for assessing protection in vaccinated children. The goal is to fine-tune our understanding of varicella immunity, potentially improving the effectiveness of vaccination strategies and reducing the incidence of breakthrough infections.
U.S. Program Impact
The U.S. chickenpox vaccination program began in 1995 and has made a significant public health and economic impact. According to the CDC, chickenpox vaccines have reduced cases by 97% and decreased disease spread, hospitalizations, and deaths. Economic assessments have also documented sizable cost savings from the one-dose program. The CDC recommends two doses of varicella vaccine for children, adolescents, and adults without evidence of immunity.
Early Varicella Milestones
The National Vaccine Information Center reports that herpesvirologists believe varicella originated in Africa millions of years ago. In 1767, English physician William Heberden definitively differentiated chickenpox from smallpox and reported lifelong immunity after recovery from the infection. In 1875, Rudolf Steiner demonstrated that chickenpox was infectious to others after transferring liquid from a lesion.
Decoding Varicella Immunity: Why Accuracy Matters
The varicella vaccine has been used in Korea since 1988 and has been included in a routine vaccination program for children (with a single dose schedule) since 2005. Evaluating the effectiveness of varicella vaccines isn't as straightforward as it seems. The challenge lies in accurately measuring the body's immune response, particularly in vaccinated individuals, where the response may be lower compared to natural infection. Numerous methods exist to detect antibodies against VZV, but each has its own set of limitations regarding objectivity, sensitivity, and ease of use. Because of the need to continue to evaluate the vaccines.
- FAMA Test: Considered the gold standard but is labor-intensive and difficult to automate.
- gpEIA Test: Aims to offer a more convenient, standardized method using the WHO international standard for calibration.
- Objective: To evaluate the accuracy and reliability of the VaccZyme™ VZV gpEIA kit and compare it to the FAMA test.
Measuring Humoral and Cellular Immunity
Recent research is examining how well laboratory tests measure immunity to varicella-zoster virus. A 2024 study evaluated a flow cytometry-based fluorescent antibody to membrane antigen test for measuring humoral immunity. The study noted that the VaccZyme VZV gpEIA kit and SERION ELISA classic VZV IgG kit had been developed but were not fully validated for varicella vaccine evaluation. Other research has examined seroprevalence more than 10 years after South Korea introduced universal single-dose vaccination for children aged 12 to 15 months in 2005, as well as the immunogenicity and safety of the live attenuated MAV/06 strain in pediatric patients after chemotherapy or hematopoietic stem cell transplantation.
Limits of Commercial Testing
Although varicella vaccine has been used for more than 20 years, commercially available methods for evaluating protective immunity have been limited. One review reported that this lack of testing methods hampered determination of mass immunogenicity after vaccination. Research on the VaccZyme gpEIA Low kit further concluded that its interpretation guidelines should be re-optimized for evaluating post-vaccination immunity. These limitations complicate efforts to determine whether a laboratory result accurately reflects protection.
Different Immunity Strategies
Countries have implemented universal childhood varicella vaccination programs over the past 30 years, but their strategies differ in dosing schedules and vaccine types. The reviewed programs include one-dose and two-dose schedules, as well as monovalent and quadrivalent vaccines. Immunize.org states that children beginning at age 12 months and adults without evidence of immunity should receive two doses. A separate source reports that immunity after childhood infection typically persists for 60 or more years for most individuals, while noting that protection at the 60-year mark has not been specifically studied.
The Path Forward: Optimizing Varicella Immunity Assessment
While the VaccZyme™ VZV gpEIA kit shows promise as a reliable tool for measuring varicella antibody titers, the study highlights the need to re-evaluate current cutoff values to better align with the immune responses of vaccinated children. Optimizing these guidelines could improve the accuracy of immunity assessments, leading to more effective vaccination strategies and better protection against varicella. The information in this article provides important information on the accuracy of current testing methods for varicella immunity.
High-Risk Groups and Prevention
Varicella vaccination guidance must address high-risk groups as part of broader prevention efforts. The listed UpToDate source focuses on preventing primary varicella infection among adults, pregnant women, and immunocompromised individuals. These groups present distinct clinical and prevention considerations. The source frames vaccination as part of managing the risks associated with chickenpox in vulnerable populations.